Selected Publications
Mitchell AB, Vasilyeva A, Gajjar A, Santana VM, Stewart CF. Determining success rates of the current pharmacokinetically guided dosing approach of topotecan in pediatric oncology patients. Pediatr Blood Cancer Apr; 66(4). 2019 PMID: 30548417
Dove AP, Manole BA, Wakefield DV, Cross SJ, Doubrovin M, Shulkin BL, Merchant TE, Davidoff AM, Furman WL, Krasin MJ, Santana VM, Lucas JT Jr. Managing local-regional failure in children with high-risk neuroblastoma: A single institution experience. Pediatr Blood Cancer Dec; 65(12). 2018 PMID:30270551
Federico SM, McCarville MB, Shulkin BL, Sondel PM, Hank JA, Hutson P, Meagher M, Shafer A, Ng CY, Leung W, Janssen WE, Wu J, Mao S, Brennan RC, Santana VM, Pappo AS, Furman WL. Pilot trial of humanized anti-GD2 monoclonal antibody (hu14.18K322A) with chemotherapy and natural killer cells in children with recurrent/refractory neuroblastoma. Clin Cancer Res. Nov 1;23(21):6441-6449. 2017 PMID: 28939747
Navid F, Santana VM, Neel M, McCarville MB, Shulkin BL, Wu J, Billups CA, Mao S, Daryani VM, Stewart CF, Kunkel M, Smith W, Ward D, Pappo AS, Bahrami A, Loeb DM, Reikes J, Rao BN, Daw NC. A phase II trial evaluating the feasibility of adding Bevacizumab to standard osteosarcoma therapy. Int J Cancer Oct 1; 141(7): 1469-1477. 2017 PMID: 28631382
Davis J, Daw NC, Navid F, Billups C, Wu J, Bahrami A, Jenkins JJ, Snyder S, Reddick W, Santana VM, McCarville M, Guo J, Shulkin, B.18F-FDG uptake during early adjuvant chemotherapy predicts histologic response in pediatric and young adult patients with osteosarcoma. J Nucl Med June 13, 2017. PMID: 28611244
Conklin HA, Ashford JM, Howarth RA, Merchant TE, Ogg RJ, Santana V, Reddick WE, Wu S, Xiong X. Working memory performance among childhood brain tumor survivors: elucidating vulnerable neural systems and targets for intervention. Journal of the International Neuropsychological Society 2012 (in press).
Davidoff AM, Fernandez-Pineda I, Santana VM, Shochat SJ. The role of neoadjuvant chemotherapy in children with malignant solid tumors. Seminars in Pediatric Surgery Feb 21(1):88-99, 2012. PMCID: N/A (PMID: 22247974).
Park JR, Scott JR, Stewart CF, London WB, Naranjo A, Santana VM, Shaw PJ, Cohn SL, Matthay KK. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group Study. J Clin Oncol Nov 20;29(33):4351-7. PMCID: PMC3221519
Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM. A single-arm pilot phase II study of gefitnib and irinotecan in children with newly diagnosed high-risk neuroblastoma. Invest New Drugs Jul 28, 2011. [Epub ahead of print]. NIHMSID: NIHMS317711
Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, Quintana J, Luchtman-Jones L, Villarroel M, Santana VM. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children’s Research Hospital OS99 Trial. Cancer Jan 10 [epub ahead of print] 2011. PMCID: N/A (PMID: 21225868).
Biermann JS, Adkins DR, Benjamin RS, Brigman B, Chow W, Conrad EU 3rd, Frassica DA, Frassica FJ, George S, Hande KR, Hornicek FJ, Letson GD, Mayerson J, McGarry SV, McGrath B, Morris CD, O’Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, Somaiah N, Yasko AW. Bone Cancer. National Comprehensive Cancer Network Bone Cancer Panel. J Natl Compr Canc Netw Jun; 8(6):688-712, 2010. PMCID: N/A (PMID: 20581300).
Robbins JR, Krasin MJ, Pai Panadiker AS, Watkins A, Wu J, Santana VM, Furman WL, Davidoff AM, McGregor LM. Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children’s Research Hospital experience. J Pediatr Surg Apr: 45(4): 678-86, 2010. PMCID:PMC2897834 NIHMSID: NIHMS200953
Navid F, Santana VM, Barfield RC. Anti-GD2 Antibody Therapy for GD2-Expressing Tumors. Curr Cancer Drug Targets Mar 1; 10(2): 200-9, 2010. PMCID: PMC2888262, NIHMSID: NIHMS 198855
Adderson EE, Rowland C, McGregor LM, Santana VM. Zygomycosis originating from an odontogenic infection in a pediatric oncology patient. Diagn Microbiol Infect Dis May;67(1):92-4, 2010. Epub 2010 Mar 12. PMCID:N/A (PMID: 20227220)
Spunt SL, Irving H, Frost J, Sender L, Guo M, Yang BB, Dreiling L, Santana VM. Pegfilgrastim-Supported VAdriaC/IE Chemotherapy in Pediatric Sarcoma Patients: a Phase 2, Randomized, Open-Label Study. J Clin Oncol Mar 10;28(8):1329-36, 2010. PMCID: PMC2834494
Furman WL, Navid F, Daw NC, McCarville MB, McGregor LM, Spunt SL, Rodriguez-Galindo C, Panetta JC, Crews KR, Wu J, Gajjar AJ, Houghton PJ, Santana VM, Stewart CF. A tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors. J Clin Oncol Sep 27(27): 4599-604, 2009. PMCID: PMC2754908
Lopes LF, Pacheco CR, Pontes EM, dos Santos S, Mastelaro MJ, Melaragno R, Rossi SM, Aevedo P, Menodca N, Alemeida MT, Sonaglio V, Ribeiro KCB, Santana VM, Schneider DT, de Camargo B. Cisplatin and Etoposide in Childhood Germ Cell Tumor: Brazilian Pediatric Oncology Society Protocol GCT-91. J Clin Oncol 27(8):1297-303, 2009. PMCID: N/A (PMID: 19164215)
Roberson JR, Kaste SC, Santana VM, Furman WL. Differential diagnosis and work-up of elevations of alkaline phosphatase following therapy for pediatric cancer. Pediatr Blood Cancer Dec;51(6):840-842, 2008. PMCID:N/A NIHMSID: NIHMS75301
Last update: September 2019